The evaluation of PSMA expression through immunohistochemistry can be an accurate and accessible tool in identifying sarcoma patients for PSMA-targeting PET/CT scans and in whom the benefit of PSMA-targeted radioligand therapy may be explored. The gene discussed is FOLH1; the disease is sarcoma.